aTyr’s Steroid-Sparing Lung Disease Drug Disappoints in Late-Stage Trial
aTyr Pharma's Phase 3 EFZO-FIT study for efzofitimod has completed patient visits, with topline results expected in Q3 2025
The study investigates efzofitimod for pulmonary sarcoidosis, aiming to reduce steroid use and improve patient outcomes
The company plans to engage with the FDA to determine the path forward for efzofitimod.